Y Intercept Hong Kong Ltd Buys Shares of 37,252 Johnson & Johnson $JNJ

Y Intercept Hong Kong Ltd bought a new stake in Johnson & Johnson (NYSE:JNJ) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 37,252 shares of the company’s stock, valued at approximately $5,690,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its holdings in shares of Johnson & Johnson by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company’s stock valued at $38,800,371,000 after buying an additional 1,170,120 shares during the period. Northern Trust Corp raised its holdings in shares of Johnson & Johnson by 0.4% in the 1st quarter. Northern Trust Corp now owns 30,943,820 shares of the company’s stock valued at $5,131,723,000 after buying an additional 130,645 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Johnson & Johnson by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock valued at $3,844,580,000 after buying an additional 4,842,582 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Johnson & Johnson by 3.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company’s stock valued at $3,133,602,000 after buying an additional 712,181 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its holdings in shares of Johnson & Johnson by 2.5% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company’s stock valued at $3,031,955,000 after buying an additional 448,666 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Down 0.0%

JNJ opened at $190.31 on Tuesday. The business has a 50 day moving average price of $182.54 and a two-hundred day moving average price of $166.65. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The company has a market cap of $458.50 billion, a PE ratio of 18.37, a P/E/G ratio of 2.24 and a beta of 0.40. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $194.48.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. UBS Group boosted their target price on Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a research note on Tuesday, October 14th. Royal Bank Of Canada reissued an “outperform” rating and set a $209.00 target price on shares of Johnson & Johnson in a research note on Friday, October 10th. Weiss Ratings raised Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Cowen reissued a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. Finally, Daiwa Capital Markets raised Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price for the company in a research note on Monday, October 20th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $199.05.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.